Alan Mateo bought $446K of 10x Genomics (TXG)
Executed Feb 21 2025, disclosed Feb 25 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 25 2025), the stock returned -13.4% (delay-adjusted); from the execution session (Feb 21 2025), -10.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Alan Mateo (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in 10x Genomics, Inc. (TXG). Across 1 priced purchase filing, the average 21-session return was -10.5% from execution and -13.4% from disclosure (delay-adjusted; derived). The largest single filing was $446K of TXG (40,000 sh × $11.14, as filed), executed Feb 21 2025.
Healthcare · 10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→